FDA Boxed Warnings: Should Package Inserts Include Levels of Evidence?

Area of Science:

• Dermatology
• Pharmacovigilance
• Regulatory Science

Background:

• Boxed warnings are the most severe FDA drug safety alerts.
• Some dermatology medications carry boxed warnings without sufficient or with contradictory evidence.

Purpose of the Study:

• To highlight the issue of non-evidence-based boxed warnings in dermatology medications.
• To advocate for FDA transparency regarding the evidence supporting these warnings.

Main Methods:

• Review of current literature and FDA labeling practices for dermatology medications.
• Analysis of the evidentiary basis for existing boxed warnings.

Main Results:

• Identified several dermatology medications with boxed warnings lacking supporting evidence.
• Observed that these warnings persist despite the absence of scientific justification.

Conclusions:

• Non-evidence-based boxed warnings contribute to medication hesitancy and undertreatment in dermatology.
• Urgent call for increased FDA transparency and evidence-based drug safety communications.